Analytical Strategy as a Competitive Advantage in Biologics Development

Key Takeaways

• Strong analytical strategy allows biologics developers to make process and formulation decisions with greater confidence by distinguishing genuine product changes from analytical and biological variability.

• Phase-appropriate analytical development should prioritize the product and process uncertainties with the greatest potential consequences rather than treating early development as an opportunity for minimal testing.

• Statistical rigor, appropriate replication, orthogonal methods, and potency strategies grounded in biological function can prevent development teams from acting on misleading or incomplete analytical information.

• Advanced technologies including next-generation sequencing, flow cytometry, particle characterization, and mass spectrometry are expanding visibility into product heterogeneity, genetic stability, impurities, and other attributes that can affect manufacturing and clinical development.

• The greatest long-term value of analytical strategy comes from converting reliable measurements into product and process knowledge that can guide development, support comparability, accelerate troubleshooting, and ultimately inform more robust manufacturing.

A development team can only make a process decision as confidently as it can measure the result. Changes in cell culture, purification, formulation, materials, or manufacturing conditions may appear to improve yield, stability, purity, potency, or another attribute, but those conclusions depend on analytical methods capable of distinguishing genuine product differences from normal analytical and biological variability.

Analytical scientists therefore need to participate from the planning stages of process development. Their role includes selecting methods appropriate to the product matrix, understanding potential sources of interference, establishing the precision required for a particular question, and determining a replication strategy capable of producing statistically meaningful results. These considerations influence whether an apparent difference is substantial and reliable enough to justify changing the process.

A strong analytical strategy also requires methods that can provide useful information quickly enough to influence development. Broadly applicable methods can reduce repeated development work, while faster analytical approaches can shorten feedback loops when teams are comparing process conditions or formulations. The technology itself is only part of the equation. Scientists need enough characterization experience to select the appropriate method and interpret what the resulting data mean for the product.

For drug developers, the competitive advantage emerges in the quality and timing of those decisions. Better analytical information can allow teams to identify problems while they remain tractable, select development paths with greater confidence, and avoid repeating work because the original analytical foundation proved inadequate.

Analytical expectations appropriately increase as a product progresses toward commercialization. An early clinical program does not require every method, characterization study, and validation activity that will ultimately support a commercial product. Problems arise when phase-appropriate development is interpreted as accepting information that is too weak for the decisions being made.

The pressure to limit early analytical spending is understandable. Resources are often most constrained when development uncertainty is greatest, and emerging drug developers must decide carefully where to invest. An apparently economical analytical strategy can become expensive, however, if limited characterization allows aggregation, instability, posttranslational modifications, or other relevant product attributes to remain undetected until later development.

Insufficiently robust methods can also lead to repeat testing or force teams to reconsider decisions that were made with less reliable information than originally assumed. More consequentially, previously unrecognized degradation or other product changes can affect biological function after substantial clinical and manufacturing work has already been completed.

A risk-based strategy helps resolve that tension. Teams can identify which product and process uncertainties could materially affect product quality, functionality, manufacturability, or future development and determine where additional characterization is justified. Early-stage programs rarely have the resources to investigate every conceivable variable, but they can focus analytical investment on questions with the greatest potential consequences.

That approach gives analytical strategy considerable leverage. Finding an instability issue before formulation is locked or recognizing a poorly understood impurity before later clinical development can preserve options that become progressively more expensive to recover.

Analytical methods do not all generate the same degree of precision, and biological and cell-based methods can carry substantial inherent variability. The experimental strategy therefore must account for how much fluctuation is expected before development teams decide that one condition truly performs better than another.

Formulation development provides a practical example. Viral infectious-titer assays may show relatively wide variability. If candidate formulation buffers are compared using too few replicates, an apparent difference in titer may reflect assay fluctuation rather than a genuine effect of the buffer. A process-development team could then select a formulation on the basis of data that were not sufficiently robust to support the choice.

Method precision, replication strategy, experimental design, and statistical interpretation are therefore integral parts of analytical development. Design of experiments (DoE) can help teams study multiple variables efficiently, but the analytical methods supporting the experiment must still provide enough resolution to identify real effects.

Orthogonal methods can add confidence when an important product characteristic is difficult to understand through a single analytical approach. Different methods may examine related attributes from different perspectives and help clarify whether an unexpected result reflects the product, the process, or the analytical procedure.

Generating more data without an appropriate experimental and statistical framework has limited value if teams still cannot determine how much confidence to place in the differences they observe.

Potency presents one of the clearest examples of the connection between analytical strategy and product understanding. For complex biologics, biological activity can depend on multiple product characteristics and several steps in the mechanism of action. Potency development therefore begins with understanding which attributes are most closely related to the product's intended biological function.

Multiple complementary assays may be valuable during early development because they can interrogate different potency-related characteristics, and the suitability of individual methods may change as the product evolves. Formulation changes, new excipients, process adjustments, or increasing product knowledge can all affect how well an assay performs.

The U.S. Food and Drug Administration's draft guidance on potency assurance for cellular and gene therapy products recommends developing multiple assays that measure known or potential potency-related critical quality attributes and evaluating them in parallel during early clinical investigations. The guidance also recognizes that redundant assays can later be discontinued as understanding improves.¹

A potency assay does not necessarily need to reproduce the product's entire mechanism of action. The analytical strategy should instead remain informed by that mechanism and provide appropriate coverage of the attributes associated with biological activity. For complex products, that may require a combination of biological and physicochemical measurements. Maintaining sufficient overlap among analytical approaches can also help teams interpret potency results when methods need to change as the product or process evolves.

Platform analytical procedures can reduce repeated development work when successive products are sufficiently similar. Prior knowledge of method performance, matrix effects, sources of interference, operating conditions, and variability can allow teams to move more quickly while maintaining an appropriate analytical standard.

The opportunity is greatest for closely related products. Recombinant modified vaccinia Ankara vaccine constructs that differ primarily in the encoded antigen, for example, may allow some established analytical approaches to transfer readily. Other attributes, including identity, target-antigen expression, or potency, may still require product-specific methods.

Current analytical-development frameworks support this risk-based use of prior knowledge. International Council for Harmonisation (ICH) Q14 addresses analytical procedure development and the use of platform analytical procedures, while ICH Q2(R2) establishes the corresponding validation framework.^2,3 PDA/ANSI Standard 07-2026 specifically addresses analytical procedure transfer, comparability, and the use of platform analytical procedures for biologics.⁴

The efficiency comes from knowing what has already been learned and where that knowledge remains applicable. A mature platform helps teams avoid repeating analytical development that adds little new information while recognizing when a different product requires additional work.

Release testing answers essential questions about product quality, but analytical development has a broader role when it remains closely connected with process development. Analytical data can help explain how the process behaves, whether a manufacturing change actually altered the product, and where unexpected product characteristics may have originated.

This requires continuous interaction between analytical and process development teams. Method selection, experimental design, and process changes should be coordinated early enough that the analytical strategy can answer the questions the development program is asking. Where highly critical attributes are involved, orthogonal methods and statistically robust experiments can provide additional confidence.

Unexpected product behavior can make that relationship particularly important. In modified vaccinia Ankara programs, for example, introduction of a transgene intended to create the desired biological effect can also alter other product behavior, including excessive aggregation that complicates formulation. Analytical characterization helps reveal these secondary consequences and provides information needed to determine whether the process or formulation should change.

That same analytical depth becomes valuable during troubleshooting. When a manufacturing result falls outside expectations, analytical development can help distinguish among possible causes, identify additional measurements that may resolve the uncertainty, and feed those findings back into process optimization.

At IDT Biologika, analytical development works alongside process development, routine production, and quality control throughout the product life cycle. That integration allows analytical insight to contribute to development decisions as well as investigation and root-cause analysis.

For drug developers, the distinction between analytical testing and analytical development is consequential. Instrument availability establishes what can be measured. Analytical expertise determines what should be measured, whether the result is reliable enough to support a decision, and what action the result should prompt. In practice, that can mean resolving technical questions faster, avoiding development choices that later need to be revisited, and identifying where additional work is actually warranted.

Improved analytical technologies are allowing development teams to examine aspects of complex biologics that once remained poorly resolved. In viral manufacturing, infectious titer historically provided an important measure of production success. Genomic and capsid titers can now add information about viral populations and defective particles, creating a more detailed picture of what the manufacturing process produced.

The same principle extends across different analytical questions. Sequencing can provide information about genetic identity, stability, mutations, and potential contaminants. Flow cytometry and related methods can provide quantitative insight into viral populations and process variation. Chromatographic and particle-characterization approaches can reveal size distributions, aggregation, or empty/full capsid populations. Mass spectrometry can help characterize host-cell proteins and posttranslational modifications.

Additional characterization becomes particularly valuable when routine release methods cannot explain unexpected behavior. IDT has developed capabilities across these areas, including next-generation sequencing (NGS), polymerase chain reaction (PCR)-based approaches, droplet digital PCR, flow cytometry, chromatographic methods, particle analysis, and mass spectrometry, supplemented by specialized external technologies where appropriate.

NGS provides a useful example of how an emerging technology can expand from research applications into regulated pharmaceutical analytics. Applications include genetic characterization, identity, mutation analysis, genetic stability, and adventitious-agent testing. European Pharmacopoeia General Chapter 2.6.41, which entered into force in April 2026, establishes a framework for high-throughput sequencing in the detection of viral extraneous agents.⁵

Properly validated NGS approaches can also replace certain conventional in vivo adventitious-agent tests and reduce reliance on animal-based testing. IDT has established a good manufacturing practice (GMP)-validated NGS-based workflow for adventitious-virus testing, extending the use of sequencing into regulated testing.

The larger value of these technologies lies in the questions they allow development teams to answer. Greater analytical resolution can expose product heterogeneity, impurities, instability, or manufacturing effects that might otherwise emerge only after they create a more visible development problem.

Biologics rarely reach commercialization without changes to the process, scale, formulation, manufacturing site, or analytical methods. Each change raises a basic analytical question: has the product itself changed, or has the way the product is being measured changed?

Suitable control or reference materials, overlapping methods, and sufficient historical data can help teams answer that question across process modifications and analytical transitions. Manufacturing changes should be assessed for their potential impact on product quality, with the extent of comparability work determined by the nature and risk of the change.⁶

Analytical methods may also need to evolve as product knowledge increases. A newer approach may offer greater specificity or sensitivity, or a formulation change may make an established method unsuitable. Bridging old and new analytical approaches allows teams to adopt better methods without losing the ability to interpret the product's development history.

In-process measurements and product attributes, such as genome and infectious titers, can also link analytical understanding across manufacturing stages. Maintaining sufficiently aligned approaches helps teams interpret later results against a coherent body of historical data.

That accumulated analytical history becomes more valuable as development decisions build on one another. It provides evidence of how the product has responded to previous changes and where important sources of variability have emerged.

Development and manufacturing now generate increasingly diverse sets of analytical and process data. Batch results, trend analyses, in-process controls, process parameters, environmental information, and additional characterization can all contain relationships relevant to product quality and manufacturing performance.

The challenge is increasingly one of interpretation. Deviations or changes in product behavior may reflect several interacting variables, while the volume of historical data can make important correlations difficult to identify manually. Artificial intelligence (AI) and advanced analytics may eventually help scientists examine these relationships more systematically.

During analytical and process development, such tools could help identify variables associated with product behavior, recognize patterns across historical batches, suggest potential causes of deviations, or focus subsequent experimental work. Online and inline analytical technologies could add further information by providing greater visibility into processes while they are running.

The field remains relatively immature, however. Analytical and manufacturing data sets need sufficient quality, structure, and context before sophisticated models can produce reliable insight. Correlation also does not establish scientific causation. Expert interpretation remains essential, particularly when previously undocumented anomalies, unusual cell behavior, or unexpected product characteristics emerge.

IDT's continued investment in automation and digitalization is intended to connect increasingly rich analytical information more closely with manufacturing data, creating additional opportunities to understand the variables that influence process robustness, yield, impurities, and potency.

As analytical resolution improves and these data sets become more connected, development teams should gain better opportunities to recognize risk, understand variability, and refine manufacturing while changes remain practical. The value of analytical strategy lies in converting measurement into knowledge early enough for that knowledge to influence development.

1. Potency Assurance for Cellular and Gene Therapy Products: Draft Guidance for Industry. U.S. Food and Drug Administration. Dec. 2023.

2. ICH Harmonised Guideline Q14: Analytical Procedure Development. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 1 Nov. 2023.

3. ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 1 Nov. 2023.

4. Krause, Stephan, et al. “PDA/ANSI Standard 07-2026: Analytical Procedure Transfer, Comparability, and the Use of Platform Analytical Procedures for Biologics.” Parenteral Drug Association. Apr. 2026. ISBN 978-1-945584-62-6.

5. “2.6.41. High-Throughput Sequencing for the Detection of Viral Extraneous Agents.” European Pharmacopoeia, Issue 12.2. 20 Oct. 2025. European Directorate for the Quality of Medicines and HealthCare.

6. ICH Harmonised Tripartite Guideline Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 18 Nov. 2004.